Shield Therapeutics Gestion

Gestion contrôle des critères 3/4

Le PDG Shield Therapeutics est Anders Lundstrom, nommé en Jul2024, a un mandat de moins d'un an. détient directement 0.001% des actions de la société, d'une valeur de € 347.40. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.6 ans et 4 ans.

Informations clés

Anders Lundstrom

Directeur général

US$53.5k

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	less than a year
Propriété du PDG	0.001%
Durée moyenne d'occupation des postes de direction	1.6yrs
Durée moyenne du mandat des membres du conseil d'administration	4yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Anders Lundstrom (62 yo)

less than a year

Titularisation

US$53,542

Compensation

Mr. Anders Lundstrom has been Interim Chief Executive Officer of Shield Therapeutics plc since July 24, 2024 and serves as its Independent Non-Executive Director since May 10, 2021. Mr. Lundstrom joined Or...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Anders Lundstrom	Interim CEO & Independent Non-Executive Director	less than a year	US$53.54k	0.0013% € 347.4
Christian Schweiger	Co-Founder & Non Executive Director	16.8yrs	US$47.17k	1.49% € 404.4k
Santosh Shanbhag	Chief Financial Officer	less than a year	pas de données	pas de données
Lucy Huntington-Bailey	General Counsel & Company Secretary	7.2yrs	pas de données	pas de données
Suzanne Wood	Group HR Director	no data	pas de données	pas de données
Carol Akinola	Head of Pharmacovigilance & Medical Information	no data	pas de données	pas de données
Andrew Hurley	Chief Commercial Officer	1.6yrs	pas de données	pas de données
Kate Armanetti	Senior Director of People & Culture	no data	pas de données	pas de données

1.6yrs

Durée moyenne de l'emploi

56.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 1JS n'est pas considérée comme expérimentée (ancienneté moyenne 1.6 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Anders Lundstrom	Interim CEO & Independent Non-Executive Director	3.5yrs	US$53.54k	0.0013% € 347.4
Christian Schweiger	Co-Founder & Non Executive Director	4.4yrs	US$47.17k	1.49% € 404.4k
Hans Hasler	Independent Non Executive Chairman	6.3yrs	US$119.83k	0.70% € 190.9k
Rudolf Widmann	Non-Executive Director	less than a year	pas de données	pas de données
Peter Llewellyn-Davies	Independent Non-Executive Director	8.8yrs	US$76.49k	0.023% € 6.2k
Christoph Gasche	Notable Scientific Advisory Board	no data	pas de données	pas de données
Maria Lacerca-Allen	Independent Non-Executive Director	3.5yrs	US$47.17k	0.035% € 9.4k
Geoffrey Block	Notable Scientific Advisory Board	no data	pas de données	pas de données
Michael Stockham	Notable Scientific Advisory Board	no data	pas de données	pas de données
Jonathon Powell	Notable Scientific Advisory Board	no data	pas de données	pas de données

4.0yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 1JS sont considérés comme expérimentés (ancienneté moyenne 4 ans).

Shield Therapeutics Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Shield Therapeutics plc Announces CEO Changes

Rudolf Widmann Joins Board of Shield Therapeutics plc as Non-Executive Director

Insufficient new directors

Shield Therapeutics plc, Annual General Meeting, Jun 20, 2024

Shield Therapeutics Appoints Santosh Shanbhag as New CFO, Effective January 16, 2024

Independent Non Executive Chairman recently bought €140k worth of stock

Recent updates

No longer forecast to breakeven

New minor risk - Profitability

Shield Therapeutics plc Announces Health Canada Approves ACCRUFeR as Prescription Drug for the Treatment of Adults with Iron Deficiency Anemia

Shield Therapeutics plc to Report First Half, 2024 Results on Sep 04, 2024

Now 29% overvalued after recent price rise

Shield Therapeutics plc Announces CEO Changes

Rudolf Widmann Joins Board of Shield Therapeutics plc as Non-Executive Director

Insufficient new directors

Shield Therapeutics plc, Annual General Meeting, Jun 20, 2024

Full year 2023 earnings released: US$0.05 loss per share (vs US$0.21 loss in FY 2022)

Shield Therapeutics plc to Report Fiscal Year 2023 Final Results on May 10, 2024

New minor risk - Financial data availability

Shield Therapeutics plc to Report Fiscal Year 2023 Final Results on Apr 30, 2024

Shield Therapeutics Appoints Santosh Shanbhag as New CFO, Effective January 16, 2024

Independent Non Executive Chairman recently bought €140k worth of stock

New major risk - Financial position

Shield Therapeutics plc Announces Hans-Peter Rudolf Is Standing Down from His Role as Chief Financial Officer on 20 October 2023

Shield Therapeutics plc has completed a Follow-on Equity Offering in the amount of £5.109782 million.

First half 2023 earnings released: US$0.025 loss per share (vs US$0.069 loss in 1H 2022)

Shield Therapeutics plc has completed a Follow-on Equity Offering in the amount of £4.991445 million.

New major risk - Financial position

Shield Therapeutics plc to Report First Half, 2023 Results on Sep 28, 2023

Shield Therapeutics plc to Report First Half, 2023 Results on Sep 28, 2023

Shield Therapeutics plc, Annual General Meeting, Jun 28, 2023

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

No longer forecast to breakeven

No longer forecast to breakeven

Shield Therapeutics plc Announces Regulatory Pathway and Timelines for Accrufer® Approval in the Republic of Korea

Shield Therapeutics plc Announces That Shelf-Life for Accrufer® Extended to 48 Months

No longer forecast to breakeven

First half 2022 earnings released: UK£0.05 loss per share (vs UK£0.04 loss in 1H 2021)

Shield Therapeutics plc to Report First Half, 2022 Results on Sep 08, 2022

Shield Therapeutics plc Announces New Drug Submission Accepted by Health Canada

Full year 2021 earnings released: UK£0.09 loss per share (vs UK£0.022 loss in FY 2020)

Shield Therapeutics plc, Annual General Meeting, Jul 27, 2022

Shield Therapeutics plc to Report Fiscal Year 2021 Results on Jun 30, 2022

Forecast breakeven date pushed back to 2024

Executive Director Timothy Watts has left the company

First half 2021 earnings released: UK£0.04 loss per share (vs UK£0.027 profit in 1H 2020)

Shield Therapeutics plc Confirms to Launch Accrufer® in the US on July 1, 2021

Shield Therapeutics (Stx): Accrufer Launch on Schedule

Shield Therapeutics plc Confirms It Remains on Track to Launch Accrufer® in the US by End of June 2021

Shield Therapeutics plc Announces Study Results in Inflammatory Bowel Diseases

Full year 2020 earnings released: UK£0.02 loss per share (vs UK£0.075 loss in FY 2019)

Shield Therapeutics plc has completed a Follow-on Equity Offering in the amount of £4.183919 million.

Shield Therapeutics plc Announces Australia's Therapeutic Goods Administration Approves Feraccru to Treat Iron Deficiency with or Without Anaemia in Adults

Independent Non Executive Chairman recently bought €87k worth of stock

New 90-day low: €0.49

Shield Therapeutics plc has completed a Follow-on Equity Offering in the amount of £25 million.

CEO & Director recently bought €68k worth of stock

New 90-day low: €0.55

CEO & Director recently bought €76k worth of stock

New 90-day low: €1.13

New 90-day high: €1.67

New 90-day high: €1.51

First half earnings released

New 90-day high - €1.44

New 90-day high - €1.28

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen